一名血小板衍生生长因子受体β（PDGFRB）相关慢性白血病患者的新型t(5;19)易位：对治疗策略的影响
Novel t(5;19) Translocation in a Patient with PDGFRB Associated Chronic Leukemia: Implications for Treatment Strategy.
作者信息
Provenzano Joel D, Kuebler J Phillip
机构信息
Riverside Methodist Hospital, Columbus, OH, USA ; Pulmonary Critical Care Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
出版信息
Case Rep Hematol. 2013;2013:709164. doi: 10.1155/2013/709164. Epub 2013 Jul 10.
Abstract
Myeloproliferative disorders are variable disorders, based on the genetic abnormality present and the cell line progenitors that are affected. In this case, we discuss a novel gene translocation in the subset of PDGFRB mutations, first seen with prominent hyperbasophilia. This case demonstrates the possibility for lower therapeutic doses of imatinib mesylate than previously reported, in order to control leukocyte counts and reverse the genetic mutation.
摘要
骨髓增殖性疾病是基于存在的基因异常和受影响的细胞系祖细胞而表现各异的疾病。在本病例中，我们讨论了血小板衍生生长因子受体β（PDGFRB）突变亚组中的一种新型基因易位，首次发现时伴有显著的嗜碱性粒细胞增多。该病例表明，与先前报道相比，使用更低治疗剂量的甲磺酸伊马替尼来控制白细胞计数并逆转基因突变是有可能的。
相似文献
1
Novel t(5;19) Translocation in a Patient with PDGFRB Associated Chronic Leukemia: Implications for Treatment Strategy.一名血小板衍生生长因子受体β（PDGFRB）相关慢性白血病患者的新型t(5;19)易位：对治疗策略的影响
Case Rep Hematol. 2013;2013:709164. doi: 10.1155/2013/709164. Epub 2013 Jul 10.
2
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.血小板衍生生长因子受体β重排的慢性骨髓增殖性疾病患者对甲磺酸伊马替尼的反应
N Engl J Med. 2002 Aug 15;347(7):481-7. doi: 10.1056/NEJMoa020150.
3
Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.在一例嗜酸性粒细胞增多性髓系肿瘤中发现伴有NUMA1-PDGFRB融合的新型t(5;11)(q32;q13.4)，该患者对甲磺酸伊马替尼有反应。
Cancer Genet. 2017 Apr;212-213:38-44. doi: 10.1016/j.cancergen.2017.03.004. Epub 2017 Mar 27.
4
Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.儿童患者同时患有骨髓增生性疾病和淋巴母细胞淋巴瘤，伴有 CCDC88C-PDGFRB 融合基因，对伊马替尼持续反应。
Acta Haematol. 2019;141(2):119-127. doi: 10.1159/000495687. Epub 2019 Feb 6.
5
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.鉴定和功能表征嗜酸粒细胞相关髓系/淋巴肿瘤中的伊马替尼敏感的 DTD1-PDGFRB 和 CCDC88C-PDGFRB 融合基因。
Genes Chromosomes Cancer. 2014 May;53(5):411-21. doi: 10.1002/gcc.22153.
6
A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).一名患有t(2;5)(q37;q31)的慢性嗜酸性粒细胞白血病患者中涉及PDGFRB和GCC2的一种新型融合基因。
Mol Genet Genomic Med. 2019 Apr;7(4):e00591. doi: 10.1002/mgg3.591. Epub 2019 Jan 29.
7
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.血小板衍生生长因子受体β（PDGFRB）融合基因阳性且BCR-ABL阴性的慢性骨髓增殖性疾病患者对伊马替尼的持久反应。
Blood. 2007 Jan 1;109(1):61-4. doi: 10.1182/blood-2006-05-024828. Epub 2006 Sep 7.
8
Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.在BCR-ABL阴性慢性骨髓增殖性疾病中破坏血小板衍生生长因子受体β（PDGFRB）基因的新型易位。
Br J Haematol. 2003 Jan;120(2):251-6. doi: 10.1046/j.1365-2141.2003.04051.x.
9
Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene.伴CCDC6-PDGFRB融合基因新断点的t(5;10)(q33;q22)的PDGFRB重排的髓系/淋系肿瘤
Intern Med. 2019 Dec 1;58(23):3449-3453. doi: 10.2169/internalmedicine.3220-19. Epub 2019 Jul 22.
10
Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.一名血小板衍生生长因子受体β相关急性髓系白血病患者对甲磺酸伊马替尼有显著反应。
Int J Hematol. 2017 May;105(5):697-701. doi: 10.1007/s12185-016-2167-z. Epub 2016 Dec 20.
引用本文的文献
1
Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.针对伊马替尼难治性骨髓增生性肿瘤起始细胞的治疗性降低。
Oncogene. 2014 Nov 13;33(46):5379-90. doi: 10.1038/onc.2013.484. Epub 2013 Nov 18.
本文引用的文献
1
2
Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).在一例伴有t(5;17)(q33 - 34;q11.2)的嗜酸性粒细胞增多相关非典型骨髓增殖性肿瘤中鉴定出MYO18A - PDGFRB融合基因。
Genes Chromosomes Cancer. 2009 Feb;48(2):179-83. doi: 10.1002/gcc.20629.
3
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.血小板衍生生长因子受体β（PDGFRB）融合基因阳性且BCR-ABL阴性的慢性骨髓增殖性疾病患者对伊马替尼的持久反应。
Blood. 2007 Jan 1;109(1):61-4. doi: 10.1182/blood-2006-05-024828. Epub 2006 Sep 7.
4
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.嗜酸性疾病中的FIP1L1-PDGFRA：常规临床实践中的患病率、伊马替尼治疗的长期经验及文献综述
Leuk Res. 2006 Aug;30(8):965-70. doi: 10.1016/j.leukres.2005.11.011. Epub 2006 Jan 6.
5
Prevalence, breakpoint distribution, and clinical correlates of t(5;12).t(5;12)的患病率、断点分布及临床相关性。
Cancer Genet Cytogenet. 2004 Sep;153(2):170-2. doi: 10.1016/j.cancergencyto.2004.01.013.
6
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.伊马替尼除bcr/abl之外的靶点及其在髓系疾病中的临床相关性。
Blood. 2004 Oct 1;104(7):1931-9. doi: 10.1182/blood-2004-01-0246. Epub 2004 May 27.
7
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.血小板衍生生长因子受体β重排的慢性骨髓增殖性疾病患者对甲磺酸伊马替尼的反应
N Engl J Med. 2002 Aug 15;347(7):481-7. doi: 10.1056/NEJMoa020150.
8
Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta.伴有5号染色体q31-35易位的骨髓增殖性疾病：血小板衍生生长因子受体β的作用
Acta Haematol. 2002;107(2):113-22. doi: 10.1159/000046641.
Zotero 插件